Climb Bio CLYM

Aoife Brennan, M.B., Ch.B., has served as our President and Chief Executive Officer and as a member of our board of directors since June 2024. Previously, Dr. Brennan served as President and Chief Executive Officer of Synlogic, Inc., a biopharmaceutical company, from October 2018 to March 2024. Prior to joining Synlogic, Inc., Dr. Brennan served as Vice President and Head of the Rare Disease Innovation Unit at Biogen where her responsibilities included the global marketing approvals of ALPROLIX, ELOCTATE and SPINRAZA as well as the advancement of several early-phase programs and external collaborations. She has served on the board of directors of Xilio Therapeutics, Inc. since June 2024. Dr. Brennan also served as a director of Synlogic, Inc. from October 2018 to March 2024 and of Fibrogen Inc. from August 2020 to June 2025. Dr. Brennan holds a medical degree from Trinity College, Dublin, Ireland and completed residency and fellowship training in general internal medicine and endocrinology. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program.

Perrin Wilson, Ph.D. has served as our Chief Business Officer since February 2025. She acted as a consultant for Climb Bio, Inc. from November 2024 to February 2025. Prior to Climb Bio, she served as Senior Vice President, Business Development and Strategy at Nuvalent, Inc., a clinical-state biopharmaceutical company, from September 2023 to September 2024. Prior to that, she served as Head of Forma Business Development and Integration Management Office, Vice President Business Development and Senior Director Global Marketing, Sickle Cell Disease Strategy at Forma Therapeutics, Holdings, Inc. (which was acquired by Novo Nordisk A/S in October 2022) from July 2021 to September 2023. Before that, she served in various business development and commercial roles at Takeda Pharmaceutical Company Limited, a pharmaceutical company, from June 2014 to June 2021 and Forest Laboratories, Inc., a pharmaceutical company, from July 2007 to June 2014. She received her B.Sc. from Lafayette College and Ph.D. from The Rockefeller University.

Susan Altschuller, Ph.D., MBA, 44, has served as the Company's Chief Financial Officer since October 2025.Dr. Altschuller, the Company's Chief Financial Officer and principal financial officer, will also serve as the Company's principal accounting officer, effective as of the 30 April 2026. She most recently served as Chief Financial Officer of Dragonfly Therapeutics, Inc., a private biotechnology company, from August 2024 to December 2024. Prior to that, she served as the Chief Financial Officer of Cerevel Therapeutics, Inc., or Cerevel, a publicly traded clinical-stage biopharmaceutical company, from May 2023 until its acquisition by AbbVie Inc. in August 2024. Prior to joining Cerevel, Dr. Altschuller was Chief Financial Officer of ImmunoGen, Inc., or ImmunoGen, a publicly traded biopharmaceutical company, from July 2020 to March 2023. Before ImmunoGen, Dr. Altschuller worked at Alexion Pharmaceuticals, Inc., a global biopharmaceutical company, where she served as Head of Enterprise Finance from April 2020 to July 2020 and Head of Investor Relations from January 2018 to April 2020. Dr. Altschuller holds a BSE in Biomedical Engineering with honors from Tulane University, a Ph.D. in biomedical engineering from the Illinois Institute of Technology, and an MBA from the MIT Sloan School of Management. She previously served as a director of Mural Oncology plc from November 2023 to September 2024 and is a founding board member of the HNRNP Family Foundation.

Douglas Williams, Ph.D., has been a member of our board of directors since November 2024, and currently serves as our chair. Dr. Williams has served as the Chief Scientific Officer of Kamino Therapeutics, Inc., a biotechnology company, since February 2026. Prior to this role, Dr. Williams was most recently the President of Research and Development at Sana Biotechnology, Inc., a cell therapy company from April 2023 to April 2024. He was the Founding President, Chief Executive Officer and a member of the board of directors of Codiak BioSciences, Inc., a biopharmaceutical company, from September 2015 to April 2023. He has also served as Executive Vice President of Research and Development at Biogen Inc., or Biogen, a biotechnology company, from 2011 to 2015. Prior to Biogen, he was CEO at ZymoGenetics, Inc. and led its acquisition by Bristol Myers Squibb Company. He has also held a variety of leadership positions, including Chief Scientific Officer and Executive Vice President of Research and Development at Seattle Genetics (acquired by Pfizer Inc. in 2023), Senior Vice President and Washington Site Leader at Amgen Inc. and Executive Vice President and Chief Technology Officer and a member of the board of directors at Immunex (acquired by Amgen Inc. in 2001). Dr. Williams currently serves as Chair of the board of directors of Camp4 Therapeutics Corp. Dr. Williams served on the board of directors of Panacea Acquisition Corp. II from June 2021 to April 2023 and on the board of directors of AC Immune SA from June 2018 to June 2025, where he served as Chair from June 2019 until June 2025. He holds a Ph.D. from the State University of New York at Buffalo, Roswell Park Division and completed a postdoctoral fellowship at Indiana University School of Medicine.

Kimberlee (Kim) Drapkin, has been a member of our board of directors since March 2025. Ms. Drapkin most recently served as the Chief Executive Officer of Graphite Bio, Inc. from August 2023 to March 2024. She was previously the Chief Financial Officer and Treasurer of Jounce Therapeutics, Inc. from August 2015 and February 2013, respectively, until May 2023. Ms. Drapkin has served on the boards of directors of LENZ Therapeutics, Inc. since March 2024, Imugene Limited since June 2023, and Acumen Pharmaceuticals, Inc since March 2022. She previously served on the board of directors of Kineta, Inc. from June 2023 to June 2025, Graphite Bio, Inc. from July 2023 to March 2024, and Yumanity Therapeutics, Inc. from December 2020 to December 2022. Ms. Drapkin began her career at PricewaterhouseCoopers LLP, is a certified public accountant and holds a B.S. in accounting from Babson College.

Alexander (Bo) Cumbo, has been a member of our board of directors since March 2025. Mr. Cumbo has served as the President and Chief Executive Officer and as a director of Solid Biosciences Inc., or Solid Bio, a life sciences company, since December 2022. Prior to that, Mr. Cumbo served as the President and Chief Executive Officer and as a director of AavantiBio, Inc., or AavantiBio, a gene therapy company, from October 2020 to December 2022, when Solid Bio acquired AavantiBio. From January 2013 to October 2020, Mr. Cumbo held positions of increasing responsibility at Sarepta Therapeutics, Inc., a precision genetic medicine company, ultimately serving as Executive Vice President, Chief Commercial Officer. From 2011 to 2013, Mr. Cumbo served as Vice President of Sales and Treatment Education for Vertex Pharmaceuticals Incorporated, or Vertex, a biotechnology company, launching Incivek, a treatment for hepatitis C, and from 2010 to 2011, he served as Area director for Vertex. Prior to Vertex, Mr. Cumbo served in multiple commercial roles supporting the HIV, HBV and cardiovascular franchises at Gilead Sciences, Inc., a biopharmaceutical company. Mr. Cumbo served on the board of directors of Verve Therapeutics, Inc. from June 2022 until July 2025, and he currently serves on the board of directors of Vor Biopharma, Inc. Mr. Cumbo received a Bachelor of Science in Laboratory Technology from Auburn University.

Judith Dunn, Ph.D., has been a member of our board of directors since February 2021. Since October 2023, Dr. Dunn has served as President of Research and Development for Vima Therapeutics, an Atlas Venture portfolio company. Dr. Dunn previously served as Entrepreneur in Residence at Atlas Venture from January 2023 to September 2023 and from 2018 to 2021. From April 2021 to January 2023, Dr. Dunn served as President of Research and Development of Fulcrum Therapeutics, Inc., a biopharmaceutical company. From 2010 to 2018, Dr. Dunn served in various roles for F. Hoffmann-La Roche , including Vice President of Clinical Development. Dr. Dunn led Psychiatry Clinical Development at Sepracor Inc. from 2005 to 2010 and held research and commercial positions at Pfizer Inc. from 1997 to 2005. Dr. Dunn served as a member of the board of directors of Seelos Therapeutics, Inc. from May 2020 to September 2021. Dr. Dunn holds a B.S. in neurobiology from University of Rochester and a Ph.D. in Neurobiology from Wesleyan University.

Stephen Thomas, Ph.D., , has been a member of our board of directors since June 2024. He has served as Chief Executive Officer and a director of Sera Medicines, LLC, or Sera Medicines, since November 2023, which is an affiliate of RA Capital Management, L.P. and a privately held biopharmaceutical company. Dr. Thomas has served as a director of Navigator Medicines, Inc., a privately held biotechnology company, since August 2024, and previously served as Chief Executive Officer from August 2024 to February 2025. He was previously Chief Executive Officer and a director of Tenet Medicines, Inc., a privately held biopharmaceutical company from November 2023 to June 2024, which was acquired by Climb Bio. From February 2020 to January 2023, Dr. Thomas served as Chief Scientific Officer of ValenzaBio Inc., or ValenzaBio, a privately held biopharmaceutical company focused on developing antibody therapeutics for autoimmune diseases. Prior to his time at ValenzaBio, Dr. Thomas served as V.P., Head of Discovery at Cerecor, Inc. (now Avalo Therapeutics, Inc.) from September 2018 to February 2020. Prior to September 2018, Dr. Thomas co-founded and served as Chief Scientific Officer of Ichorion Therapeutics, Inc., a privately held biopharmaceutical company, which was acquired by Cerecor Inc. Dr. Thomas received a Doctor of Philosophy in Chemistry (Organic Synthesis & Chemical Biology) from Columbia University, a Master of Science in Chemistry (Organic Synthesis) from Columbia University, and a Bachelor of Science in Chemistry from Rensselaer Polytechnic Institute.

Andrew Levin, M.D., Ph.D., is a Co-Founder of Climb Bio formerly Eliem Therapeutics, Inc., served as our Chief Executive Officer from October 2018 to October 2020, and served as the Chair of our board of directors from February 2019 to November 2024 and as Executive Chair of our board of directors from February 2023 to June 2024. Since 2015, Dr. Levin has served as a Partner on the Investment Team at RA Capital Management, L.P. Previously, Dr. Levin was a Vice President at H.I.G. BioVentures, and prior to that he served as the Director of Pharmaceutical Sciences for the Clinton Health Access Initiative. Dr. Levin holds a B.S. in mechanical engineering from Princeton University, a Ph.D. in biomedical engineering from the Massachusetts Institute of Technology and an M.D. from Harvard Medical School.